XRN heads into its Q1 2026 earnings with options market participants leaning decidedly more bullish than usual — a notable shift for a healthcare REIT that has spent much of the past two months carrying a more defensive posture.
The clearest read comes from the options market. The put/call ratio has dropped to 0.35, well below its 20-day average of 0.55, suggesting call demand is dominant. That's a material swing: through mid-April, the PCR was holding above 0.85, with some readings near 0.90 — territory associated with heavier hedging. The reversal from defensive to offensive positioning unfolded quickly across the final weeks of April and has been sustained. The RSI at 52.5 is neutral, giving no technical warning against the bullish tilt.
Short interest is a secondary consideration here, not a primary one. At 4.1% of the free float, it is a modest level — and it has been shrinking. SI fell roughly 15% from its April peak of around 646,000 shares to the current 548,541, where it has been stable for two weeks. Borrowing costs are cheap at 0.46% annualised, and availability is ample, with the lending pool barely touched. There is no meaningful squeeze dynamic in play, and the borrow conditions do not signal elevated conviction among short sellers.
The fundamental picture gives bulls something to work with, but also gives bears a clear line of attack. Revenue is running at an estimated $153 million, with EBITDA near $102.5 million — solid for a REIT of this size. Cash from operations is $73.6 million. The problem is the bottom line: net income is estimated at -$4.4 million, driven partly by $34.7 million in interest expense on a $703 million net debt load. The EV/EBITDA multiple of 12.5x is not extreme for a healthcare REIT, and the forward yield sits at 8.7% — a number that draws income-focused buyers. But with a negative earnings per share (-$0.34) and a dividend score in the 24th percentile, income-oriented holders face questions about sustainability. The analyst consensus is a hold from three covering analysts, with a mean price target of $38.57 — roughly 8% above the current $35.59 close.
The three most recent past earnings reactions tell a mixed story. The February 2026 print produced a 1.8% one-day gain. The prior event in the same month saw a one-day drop of 6.9% that then partially recovered to -2.7% over five days. The event before that fell 2.3%. Recent price momentum, however, has been constructive — up 7% over the past month and outperforming peers like NHI, which fell 4.6% on the week, and SBRA, which shed 0.6%. Closer peer HR also posted a 7.2% weekly gain, suggesting the healthcare REIT space has found some support.
Today's print will test whether the operational cash flow profile and the EBITDA trajectory can justify the forward yield and absorb growing interest costs — or whether the negative net income line remains a structural ceiling for the stock.
See the live data behind this article on ORTEX.
Open XRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
